Generation of monoclonal antibodies to the anti-trypanosomal drug isometamidium
Mice were immunized with either an isometamidium-human serum albumin (HSA) conjugate or an isometamidium-porcine thyroglobulin conjugate (PTG). Thereafter, monoclonal antibodies (MAbs) IL-A 1001, IL-A 1002, IL-A 1003, 5F7.B7, and 5F7.C9 were generated and selected on the basis that they recognized c...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Journal Article |
| Language: | Inglés |
| Published: |
1994
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/10568/28676 |
| _version_ | 1855529867314987008 |
|---|---|
| author | Peregrine, A.S. Eisler, M.C. Katende, J. Flynn, J.N. Gault, E.A. Kinabo, L.D.B. Holmes, P.H. |
| author_browse | Eisler, M.C. Flynn, J.N. Gault, E.A. Holmes, P.H. Katende, J. Kinabo, L.D.B. Peregrine, A.S. |
| author_facet | Peregrine, A.S. Eisler, M.C. Katende, J. Flynn, J.N. Gault, E.A. Kinabo, L.D.B. Holmes, P.H. |
| author_sort | Peregrine, A.S. |
| collection | Repository of Agricultural Research Outputs (CGSpace) |
| description | Mice were immunized with either an isometamidium-human serum albumin (HSA) conjugate or an isometamidium-porcine thyroglobulin conjugate (PTG). Thereafter, monoclonal antibodies (MAbs) IL-A 1001, IL-A 1002, IL-A 1003, 5F7.B7, and 5F7.C9 were generated and selected on the basis that they recognized conjugated and unconjugated isometamidium, but lacked cross-reactivity with the carrier molecules. All five MAbs were of the IgG<sub>1 isotype. Each of the five MAbs was assessed in a competitive ELISA for isometamidium; in each case, the minimum level of detection was approximately 10ng/ml. Each MAb exhibited approximately 0.1% cross-reactivity with the anti-trypanosomal compound diminazene. However, based on their cross-reactivity with the anti-trypanosomal compound homidium, the MAbs could be divided into two groups; IL-A 1001, IL-A 1002, and IL-A 1003, produced using an isometamidium-HSA conjugate as an immunogen, exhibited low levels of cross-reactivity (approximately 0.1%). In contrast, 5F7.B7 and 5F7.C9, produced using an isometamidium-PTG conjugate as an immunogen, exhibited high levels of cross-reactivity. |
| format | Journal Article |
| id | CGSpace28676 |
| institution | CGIAR Consortium |
| language | Inglés |
| publishDate | 1994 |
| publishDateRange | 1994 |
| publishDateSort | 1994 |
| record_format | dspace |
| spelling | CGSpace286762022-01-29T17:19:28Z Generation of monoclonal antibodies to the anti-trypanosomal drug isometamidium Peregrine, A.S. Eisler, M.C. Katende, J. Flynn, J.N. Gault, E.A. Kinabo, L.D.B. Holmes, P.H. monoclonal antibodies trypanosomiasis drug therapy isomerization disease control animal diseases Mice were immunized with either an isometamidium-human serum albumin (HSA) conjugate or an isometamidium-porcine thyroglobulin conjugate (PTG). Thereafter, monoclonal antibodies (MAbs) IL-A 1001, IL-A 1002, IL-A 1003, 5F7.B7, and 5F7.C9 were generated and selected on the basis that they recognized conjugated and unconjugated isometamidium, but lacked cross-reactivity with the carrier molecules. All five MAbs were of the IgG<sub>1 isotype. Each of the five MAbs was assessed in a competitive ELISA for isometamidium; in each case, the minimum level of detection was approximately 10ng/ml. Each MAb exhibited approximately 0.1% cross-reactivity with the anti-trypanosomal compound diminazene. However, based on their cross-reactivity with the anti-trypanosomal compound homidium, the MAbs could be divided into two groups; IL-A 1001, IL-A 1002, and IL-A 1003, produced using an isometamidium-HSA conjugate as an immunogen, exhibited low levels of cross-reactivity (approximately 0.1%). In contrast, 5F7.B7 and 5F7.C9, produced using an isometamidium-PTG conjugate as an immunogen, exhibited high levels of cross-reactivity. 1994 2013-05-06T07:01:09Z 2013-05-06T07:01:09Z Journal Article https://hdl.handle.net/10568/28676 en Limited Access Hybridoma;13(4): 289-294 |
| spellingShingle | monoclonal antibodies trypanosomiasis drug therapy isomerization disease control animal diseases Peregrine, A.S. Eisler, M.C. Katende, J. Flynn, J.N. Gault, E.A. Kinabo, L.D.B. Holmes, P.H. Generation of monoclonal antibodies to the anti-trypanosomal drug isometamidium |
| title | Generation of monoclonal antibodies to the anti-trypanosomal drug isometamidium |
| title_full | Generation of monoclonal antibodies to the anti-trypanosomal drug isometamidium |
| title_fullStr | Generation of monoclonal antibodies to the anti-trypanosomal drug isometamidium |
| title_full_unstemmed | Generation of monoclonal antibodies to the anti-trypanosomal drug isometamidium |
| title_short | Generation of monoclonal antibodies to the anti-trypanosomal drug isometamidium |
| title_sort | generation of monoclonal antibodies to the anti trypanosomal drug isometamidium |
| topic | monoclonal antibodies trypanosomiasis drug therapy isomerization disease control animal diseases |
| url | https://hdl.handle.net/10568/28676 |
| work_keys_str_mv | AT peregrineas generationofmonoclonalantibodiestotheantitrypanosomaldrugisometamidium AT eislermc generationofmonoclonalantibodiestotheantitrypanosomaldrugisometamidium AT katendej generationofmonoclonalantibodiestotheantitrypanosomaldrugisometamidium AT flynnjn generationofmonoclonalantibodiestotheantitrypanosomaldrugisometamidium AT gaultea generationofmonoclonalantibodiestotheantitrypanosomaldrugisometamidium AT kinaboldb generationofmonoclonalantibodiestotheantitrypanosomaldrugisometamidium AT holmesph generationofmonoclonalantibodiestotheantitrypanosomaldrugisometamidium |